RIAPANTA 40/MG EC TAB 30/TAB

Indications

Approved Uses

Erosive esophagitis associated with GERD (healing) and maintenance of healing; and pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).

Off-Label Uses

Common off-label uses include H. pylori eradication as part of combination therapy, prevention/treatment of NSAID-associated ulcers (depending on local labeling), stress-ulcer prophylaxis in critically ill patients, and laryngopharyngeal reflux/functional dyspepsia (selected cases).

Dosage & Administration

Dosing by Condition

Erosive esophagitis (healing): 40 mg PO once daily for up to 8 weeks (may consider an additional 8 weeks if not healed). Maintenance of healed erosive esophagitis: 40 mg PO once daily. Pathological hypersecretory conditions (e.g., Zollinger-Ellison): start 40 mg PO twice daily and titrate; doses up to 240 mg/day may be used. H. pylori eradication: pantoprazole-based regimens exist but are typically not a labeled indication for this product (use per local guideline regimen if prescribed).

Initial Dose

40 mg orally once daily.

Maintenance Dose

20-40 mg orally once daily.

Maximum Dose

240 mg/day (for Zollinger-Ellison syndrome); 80 mg/day for standard indications

Children's Dosage

Approved for erosive esophagitis in children ≥5 years. 15 kg to <40 kg: 20 mg once daily for up to 8 weeks. ≥40 kg: 40 mg once daily for up to 8 weeks.

Dose Adjustment Notes

Renal impairment: no dosage adjustment. Hepatic impairment: no adjustment for mild-moderate; in severe hepatic impairment, use caution and consider reduced dose/monitoring (some references limit to 20 mg/day). CYP2C19 poor metabolizers: no routine dose adjustment recommended.

How to Take

Swallow the 40 mg enteric‑coated tablet whole with water; do not crush, chew, or split. Take once daily about 30-60 minutes before a meal (preferably before breakfast).

Side Effects

Common Side Effects

Headache, diarrhea, nausea, abdominal pain, flatulence, constipation, vomiting, dizziness

Side Effect Frequency

Common (1-10%): headache, diarrhea, nausea/vomiting, abdominal pain, flatulence, constipation; Uncommon (0.1-1%): dizziness, rash/pruritus, elevated liver enzymes; Rare/very rare: interstitial nephritis, severe cutaneous reactions, hypomagnesemia (typically with prolonged use), C. difficile-associated diarrhea, fractures (with long-term/high-dose use), lupus erythematosus (SCLE).

Safety & Warnings

Contraindications

Hypersensitivity to pantoprazole/other substituted benzimidazoles (PPIs) or excipients; concomitant use with rilpivirine-containing products.

Warnings & Precautions

May mask gastric malignancy (evaluate alarm features); long-term/high-dose use: increased fracture risk, hypomagnesemia (consider monitoring if prolonged/with risk factors), vitamin B12 deficiency, and C. difficile-associated diarrhea; acute interstitial nephritis and cutaneous/systemic lupus have been reported.

Age Restriction

Not approved for erosive esophagitis in children younger than 5 years (and this 40 mg tablet is generally not suitable for <5 years due to dosing/formulation).

Driving Warning

Safe

Drug Interactions

Drug Interactions

Major/avoid: rilpivirine (contraindicated), atazanavir and nelfinavir (avoid due to reduced absorption with higher gastric pH). Other clinically relevant: high-dose methotrexate (may increase levels-consider holding PPI), warfarin (monitor INR), drugs needing acidic pH for absorption (e.g., ketoconazole/itraconazole, iron salts), and clopidogrel (interaction less than omeprazole but consider risk/benefit).

Interaction Severity

MAJOR/CONTRAINDICATED: rilpivirine-containing products (avoid). MAJOR/AVOID: atazanavir or nelfinavir (reduced antiviral exposure; avoid or use specialist-directed alternatives). MODERATE: high-dose methotrexate (consider holding PPI/monitor), warfarin (monitor INR), drugs needing acidic pH for absorption (e.g., ketoconazole/itraconazole, iron salts) (reduced absorption).

Food Interaction

Take on an empty stomach about 30-60 minutes before a meal (preferably breakfast); food has limited effect on exposure but pre-meal timing improves acid suppression.

Alcohol Interaction

Safe

Special Populations

Pregnancy

Category B (no evidence of risk in animal studies; safety in human pregnancy not established; use only if clearly needed)

Breastfeeding

Consult Doctor

Children

Approved for erosive esophagitis in children ≥5 years. 15 kg to <40 kg: 20 mg once daily for up to 8 weeks. ≥40 kg: 40 mg once daily for up to 8 weeks.

Elderly

Standard adult dosing; no routine dose adjustment required. Exercise caution with long-term use due to increased risk of fractures and hypomagnesemia in elderly patients.

Kidney Impairment

No dose adjustment needed in renal impairment.

Liver Impairment

Severe hepatic impairment: consider dose reduction (commonly max 20 mg once daily) and monitor liver enzymes; mild-moderate: usually no adjustment.

Storage & Patient Advice

Storage Conditions

Store below 30°C. Keep in original packaging to protect from moisture.

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next scheduled dose, skip the missed dose and resume the regular schedule-do not double doses.

Stopping the Medicine

Short-term use: can stop when no longer needed; long-term use: consider tapering/step-down to reduce rebound acid hypersecretion.

Overdose

Usually limited symptoms consistent with adverse-effect profile; manage with symptomatic/supportive care; pantoprazole is not significantly removed by hemodialysis; seek urgent medical evaluation.

Patient Counseling

Take 1 tablet whole with water 30-60 minutes before a meal (preferably breakfast); do not crush/chew/split. Use for the prescribed duration; if long-term therapy is planned, discuss risks (low magnesium, B12 deficiency, fractures) and report severe/persistent diarrhea or symptoms of low magnesium (cramps, palpitations). Tell your clinician about all medicines, especially HIV meds (rilpivirine/atazanavir/nelfinavir), warfarin, methotrexate, azole antifungals, and iron.

Monitoring Requirements

Long-term therapy: consider magnesium at baseline and periodically (especially >1 year or with diuretics/digoxin), assess for vitamin B12 deficiency with prolonged use, monitor for bone fracture risk (and consider bone health evaluation in high-risk patients), and monitor renal function if symptoms suggest acute interstitial nephritis.

Pharmacology

Mechanism of Action

Prodrug that irreversibly (covalently) inhibits the gastric parietal cell H+/K+-ATPase (proton pump), suppressing basal and stimulated acid secretion.

Onset of Action

Onset begins within a few hours after a dose (about 2-3 hours), but maximal acid suppression typically requires 2-4 days of continuous daily dosing.

Duration of Effect

Approximately 24 hours of acid suppression per dose, with maximal effect after several days of daily dosing.

Half-Life

Approximately 1 hour (about 0.9-1.9 hours).

Bioavailability

Approximately 77%.

Metabolism

Extensively metabolized in the liver, primarily via CYP2C19 and to a lesser extent via CYP3A4 (with significant first-pass metabolism).

Excretion

Approximately 80% excreted in urine (primarily as metabolites) and ~20% in feces/bile.

Protein Binding

Approximately 98%.

Product Information

Available Dosage Forms

For RIAPANTA specifically: 40 mg enteric‑coated (delayed‑release) oral tablet. (Pantoprazole as an ingredient is also available in some markets as delayed‑release granules/oral suspension and as IV powder for injection, but those are not this product.)

Composition per Dose

Each enteric-coated tablet: 40 mg pantoprazole as pantoprazole sodium sesquihydrate

Generic Availability

Yes

OTC Alternatives

OTC alternatives (market-dependent) include antacids (e.g., aluminum/magnesium hydroxide, calcium carbonate), H2-receptor antagonists (e.g., famotidine), and OTC PPIs in some countries (e.g., omeprazole 20 mg).

Gi Condition

Acid Reflux/GERD, Ulcer

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.